EPO and anemia (phenotype): A first-line treatment to manage splenomegaly in MF is ruxolitinib (93.5%), whereas MF-associated anemia is usually treated with erythropoietin (51.6%), followed by prednisone (22.6%), thalidomide/lenalidomide (19.4%), and danazol (6.5%).